Latest Articles
GSK forays into Oncology in India with Jemperli and Zejula, Bringing Precision Therapies for Gynaecological Cancers - India Education Diary
GSK forays into Oncology in India with Jemperli and Zejula, Bringing Precision Therapies for Gynaecological Cancers India Education Diary
Published: Aug. 25, 2025, 3:28 p.m.
GSK forays into oncology in India bringing precision therapies for gynaecological cancers - BioSpectrum India
GSK forays into oncology in India bringing precision therapies for gynaecological cancers BioSpectrum India
Published: Aug. 25, 2025, 2:19 p.m.
GSK Launches Jemperli for Advanced Endometrial Cancer and Zejula for Ovarian Cancer in India - geneonline.com
GSK Launches Jemperli for Advanced Endometrial Cancer and Zejula for Ovarian Cancer in India geneonline.com
Published: Aug. 25, 2025, 12:03 p.m.
GSK forays into Oncology in India with Jemperli and Zejula, Bringing Precision Therapies for Gynaecological Cancers - APN News
GSK forays into Oncology in India with Jemperli and Zejula, Bringing Precision Therapies for Gynaecological Cancers APN News
Published: Aug. 25, 2025, 11:04 a.m.
GSK introduces Jemperli and Zejula in India to expand oncology portfolio - Express Pharma
GSK introduces Jemperli and Zejula in India to expand oncology portfolio Express Pharma
Published: Aug. 25, 2025, 11 a.m.
GSK forays into oncology in India with Jemperli and Zejula - Indian Pharma Post
GSK forays into oncology in India with Jemperli and Zejula Indian Pharma Post
Published: Aug. 25, 2025, 10:23 a.m.
GSK enters Indian oncology market with gynaecological cancer drugs - The New Indian Express
GSK enters Indian oncology market with gynaecological cancer drugs The New Indian Express
Published: Aug. 25, 2025, 8:44 a.m.
GSK India's Precision Leap in Gynaecological Cancer Care - Devdiscourse
GSK India's Precision Leap in Gynaecological Cancer Care Devdiscourse
Published: Aug. 25, 2025, 8:01 a.m.
GSK launches advanced cancer therapies Jemperli and Zejula in India - Business Upturn
GSK launches advanced cancer therapies Jemperli and Zejula in India Business Upturn
Published: Aug. 25, 2025, 5:42 a.m.
MMP2/TIMP2 ratio as a measurable indicator for differentiating diffuse adenomyosis, ovarian endometriosis, and their co-existence.
Adenomyosis and endometriosis, two common estrogen-dependent benign gynecological disorders usually present with overlapping symptoms, such as pain and infertility. These two conditions often co-exist and are associated with poor reproductive …
Published: Aug. 24, 2025, midnight
Link copied to clipboard!